MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cllc.2026.03.004

Медицинская библиотека · Clinical lung cancer · 2026

Impact of Consolidation Durvalumab on Local Control Following Chemoradiotherapy for Non-Small Cell Lung Cancer.

Zakharia Adel, Bodner William, Halmos Balazs, Garg Madhur, Gucalp Rasim, Cheng Haiying, Stiles Brendon, Ohri Nitin

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The PACIFIC trial demonstrated that durvalumab after concurrent chemoradiotherapy (CCRT) improves survival in locally advanced non-small cell lung cancer (NSCLC), but its impact on in-field local control is unclear. We reviewed outcomes with and without consolidation durvalumab to evaluate its effect on local control of treated tumors and lymph nodes.

PATIENTS AND

METHODS

We reviewed patients with locally advanced NSCLC who underwent staging FDG-PET and CCRT with or without consolidation durvalumab between 2007 and 2023. Patients with progression or death within 6 weeks postradiotherapy were excluded. Lesions were categorized as high- or low-risk using a volume cutoff of 25 cc. Kaplan-Meier and competing risks analyses were used to evaluate progression-free survival (PFS), overall survival (OS), and local progression. Tumor control probability (TCP) modeling was performed to characterize the association between lesion volume and local control.

RESULTS

Among 233 patients with 696 irradiated lesions, 88 patients (38%) received durvalumab. Median follow-up was 70 months overall and 44 months with durvalumab. Durvalumab receipt was associated with improved PFS (median 16 vs. 11 months, P = .011) and improved OS (median 50 vs. 30 months, P = .042). Durvalumab was not significantly associated with local recurrence rate on a patient level (2-year recurrence rate 12% vs. 17%, P = .361). At the lesion level, the 2-year recurrence rate was 6% overall, and high-risk lesions had greater recurrence risk (19% vs. 2%, P < .001).

CONCLUSIONS

Many patients with LA-NSCLC have little risk of in-field recurrence after chemoradiotherapy, with or without consolidation durvalumab. Bulky lesions remain prone to failure, highlighting the need for improved local control strategies in high-risk disease.

Для цитирования: Zakharia Adel, Bodner William, Halmos Balazs, Garg Madhur, Gucalp Rasim, Cheng Haiying, Stiles Brendon, Ohri Nitin. Impact of Consolidation Durvalumab on Local Control Following Chemoradiotherapy for Non-Small Cell Lung Cancer.. Clinical lung cancer. 2026. DOI: 10.1016/j.cllc.2026.03.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.